The future: Combination systemic therapy for hepatocellular carcinoma

Ahmed O. Kaseb; Melanie B. Thomas

doi:10.1007/978-1-60327-522-4_23

The future: Combination systemic therapy for hepatocellular carcinoma

Ahmed O. Kaseb, Melanie B. Thomas

GI Medical Oncology

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Hepatocellular carcinoma (HCC) is a potentially curable tumor by surgical resection, local ablation, or liver transplantation. However, the majority of patients with HCC present with advanced stage disease, which is most commonly, accompanied by severe background liver disease. Hence, curative treatments are feasible for only a small fraction of patients with localized disease.

Original language	English (US)
Title of host publication	Hepatocellular Carcinoma
Subtitle of host publication	Targeted Therapy and Multidisciplinary Care
Publisher	Springer New York
Pages	369-382
Number of pages	14
ISBN (Print)	9781603275217
DOIs	https://doi.org/10.1007/978-1-60327-522-4_23
State	Published - 2011

Keywords

Carcinogenic pathways in HCC
Combination systemic therapy
EGFR and VEGF pathways
Growth factors
HCC systemic therapy
SHARP trial
Sorafenib

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-1-60327-522-4_23

Cite this

@inbook{ca319da671494bba8c31894512871f04,

title = "The future: Combination systemic therapy for hepatocellular carcinoma",

abstract = "Hepatocellular carcinoma (HCC) is a potentially curable tumor by surgical resection, local ablation, or liver transplantation. However, the majority of patients with HCC present with advanced stage disease, which is most commonly, accompanied by severe background liver disease. Hence, curative treatments are feasible for only a small fraction of patients with localized disease.",

keywords = "Carcinogenic pathways in HCC, Combination systemic therapy, EGFR and VEGF pathways, Growth factors, HCC systemic therapy, SHARP trial, Sorafenib",

author = "Kaseb, {Ahmed O.} and Thomas, {Melanie B.}",

year = "2011",

doi = "10.1007/978-1-60327-522-4_23",

language = "English (US)",

isbn = "9781603275217",

pages = "369--382",

booktitle = "Hepatocellular Carcinoma",

publisher = "Springer New York",

}

TY - CHAP

T1 - The future

T2 - Combination systemic therapy for hepatocellular carcinoma

AU - Kaseb, Ahmed O.

AU - Thomas, Melanie B.

PY - 2011

Y1 - 2011

N2 - Hepatocellular carcinoma (HCC) is a potentially curable tumor by surgical resection, local ablation, or liver transplantation. However, the majority of patients with HCC present with advanced stage disease, which is most commonly, accompanied by severe background liver disease. Hence, curative treatments are feasible for only a small fraction of patients with localized disease.

AB - Hepatocellular carcinoma (HCC) is a potentially curable tumor by surgical resection, local ablation, or liver transplantation. However, the majority of patients with HCC present with advanced stage disease, which is most commonly, accompanied by severe background liver disease. Hence, curative treatments are feasible for only a small fraction of patients with localized disease.

KW - Carcinogenic pathways in HCC

KW - Combination systemic therapy

KW - EGFR and VEGF pathways

KW - Growth factors

KW - HCC systemic therapy

KW - SHARP trial

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=84889978586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889978586&partnerID=8YFLogxK

U2 - 10.1007/978-1-60327-522-4_23

DO - 10.1007/978-1-60327-522-4_23

M3 - Chapter

AN - SCOPUS:84889978586

SN - 9781603275217

SP - 369

EP - 382

BT - Hepatocellular Carcinoma

PB - Springer New York

ER -

The future: Combination systemic therapy for hepatocellular carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this